Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ropinirole hydrochloride
Drug ID BADD_D01967
Description Ropinirole, also known as _ReQuip_, is a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome [FDA label], [A174547]. It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 by the FDA [FDA label] for the management of Parkinson's disease. In 2005, it was the first drug approved in the US for the management of primary moderate to severe restless legs syndrome [A174547]. In 2008, the extended-release capsules of ropinirole were approved, allowing for less frequent dosing, therefore increased compliance, and offering a similar side effect profile and efficacy to previous formulations of ropinirole [A35711].
Indications and Usage For the treatment of the signs and symptoms of idiopathic Parkinson's disease. Also used for the treatment of restless legs syndrome.
Marketing Status Prescription; Discontinued
ATC Code N04BC04
DrugBank ID DB00268
KEGG ID D00784
MeSH ID C046649
PubChem ID 68727
TTD Drug ID D0R9EQ
NDC Product Code 46708-034; 63629-7152; 62332-031; 46708-036; 50090-4810; 43547-268; 0904-6373; 43547-600; 43547-269; 46708-031; 62332-035; 65096-0102; 54752-0005; 46708-032; 62332-034; 62332-033; 65841-714; 0615-8191; 0615-8190; 71335-1626; 62332-032; 61919-564; 65841-716; 46708-030; 62332-030; 43547-601; 65841-713; 0904-6374; 50090-3304; 43547-596; 0615-8188; 70518-2476; 43547-597; 55111-091; 60687-588; 63629-4798; 43547-595; 62147-0015; 60687-577; 46708-869; 43547-271; 61187-008; 58032-0133; 43547-270; 71335-0727; 43547-274; 43547-599; 0615-8189; 66039-853; 43547-273; 55154-7888; 50090-4348; 71335-0587; 62147-0008; 71335-1434; 65841-715; 46708-035; 51655-360; 43547-598; 65841-712; 62332-036; 55154-7633; 71335-0829; 65841-718; 65841-717; 43547-272; 64220-121; 46708-033
Synonyms ropinirole | 4-(2-(di-n-propylamino)ethyl)-2(3H)-indolone | ropinirol | SK&F 101468 | SKF 101468 | SK&F-101,468 | Requip | ropinirole hydrochloride
Chemical Information
Molecular Formula C16H25ClN2O
CAS Registry Number 91374-20-8
SMILES CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1.Cl
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal pain07.01.05.002--
Anxiety19.06.02.002--
Asthenia08.01.01.001--Not Available
Back pain15.03.04.005--
Blood pressure increased13.14.03.005--Not Available
Confusional state17.02.03.005; 19.13.01.001--
Constipation07.02.02.001--
Diarrhoea07.02.01.001--
Dizziness02.01.02.004; 17.02.05.003; 24.06.02.007--
Dry mouth07.06.01.002--
Dyskinesia17.01.02.006--
Dyspepsia07.01.02.001--
Fall12.01.08.002--
Fatigue08.01.01.002--
Hallucination19.10.02.002--
Headache17.14.01.001--
Heart rate abnormal13.14.04.006--Not Available
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hypertension24.08.02.001--
Hypotension24.06.03.002--
Nausea07.01.07.001--
Oedema peripheral02.05.04.007; 08.01.07.007; 14.05.06.011--
Orthostatic hypotension17.05.01.020; 24.06.03.004--Not Available
Retinal disorder06.08.03.005--Not Available
Somnolence17.02.04.006; 19.02.05.003--
Syncope02.01.02.008; 17.02.04.008; 24.06.02.012--
Vertigo04.04.01.003; 17.02.12.002--
Viral infection11.05.04.001--Not Available
Adverse event08.06.01.010--Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages